ClinicalTrials.gg
RecruitingNCT07193888Updated May 26, 2026

Navitor Japan Study

An observational study in Severe Aortic Stenosis, sponsored by Abbott Medical Devices. Recruiting at 3 sites in Japan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Valve Stenosis by Abbott — 4 open to participants now, 9 under way, none of them phase 3. Aortic Valve Stenosis · Abbott.

Started
2025
with 1 other
Observational
6 of 26
2 open now
Registered
25th of 26
by date

Among the 26 studies in Aortic Valve Stenosis by Abbott, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 25th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 26 studies in Aortic Valve Stenosis by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Valve Stenosis by Abbott, or all of them as a file.
02

Study summary

The Navitor Japan Study is designed to evaluate the safety and performance of the Navitor™ valve used in combination with the FlexNav™ delivery system in a contemporary, real-world setting.

Read the detailed description

A prospective, single-arm, observational, multicenter post-market clinical study enrolling approximately 100 Japanese patients with symptomatic, severe aortic stenosis. The study will evaluate the safety and performance of the Navitor TAVI system, including future commercially available iterations, as they become available in Japan. Enrolled subjects will undergo follow-up at discharge, 30 days and 1-year post-index procedure.

03

Conditions studied

  • Severe Aortic Stenosis

Keywords

  • NAVITOR
  • Transcatheter aortic valve implantation (TAVI)
  • Aortic Stenosis
  • Cardiovascular Disease
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic, severe aortic stenosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is eligible per the current approved indication after Heart Team discussion and intended to undergo a Navitor TAVI procedure.
  2. The patient has been informed of the nature of the study, agrees to its provisions, and has provided written as approved by the EC of the respective clinical site.
  3. The patient and the treating physician agree that the subject will return for all required post-procedure follow-up visits

Exclusion criteria

Exclusion Criteria:

  1. Patient is not eligible for the Navitor TAVI System per the current Instructions for Use (IFU).
  2. \< 12 months from the time of due to non-cardiac co-morbid conditions.
  3. In the judgment of the Investigator, patient presents with a medical, social, or psychological condition that could limit the ability or willingness to participate in the study, comply with study required testing and/or follow-up visits or that could impact scientific integrity of the study.
  4. Known for computed tomography (CT) or sensitivity to contrast media, which cannot be adequately premedicated.
  5. Inability to tolerate antiplatelet/anticoagulation therapy or nitinol alloy (nickel and titanium), which cannot be adequately premedicated.
  6. Currently participating in an drug or device study that may confound the results of this study.
  7. Anatomy that makes insertion and endovascular access to the aortic valve difficult and/or impossible.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Cohort 1

    This study will enroll subjects of all genders from the population of patients qualifying for TAVI.

    Device: Navitor Transcatheter Aortic Valve Implantation

Interventions

  • DeviceNavitor Transcatheter Aortic Valve Implantation

    Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System.

    Also known as: TAVI

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint

    The primary safety endpoint is all-cause mortality at 30 days post-TAVI procedure, which will be assessed descriptively

    Time frame: 30 days post index procedure

  2. Primary Performance Endpoint

    The primary performance endpoint is moderate or greater paravalvular leak (PVL) at 30 days as measured on a transthoracic echocardiogram (TTE) by the echocardiographic core laboratory. This endpoint will be reported as % subjects with moderate or greater PVL at 30 days.

    Time frame: 30 days post index procedure

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 33 months is close to that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Sep 26, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193888
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Oct 30, 2025
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
May 26, 2026

Study contacts

Bart Janssens
Contact
bart.janssens@abbott.com
+32471723201
Alicia Kimber
Contact
alicia.kimber@abbott.com
+1 415-917-9696

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion